Sangamo Therapeutics Receives FDA Fast Track Designation for ST-503 to Treat Intractable Pain Due to Small Fiber Neuropathy

Sangamo Therapeutics has received FDA Fast Track Designation for ST-503, an epigenetic regulator for treating intractable pain due to small fiber neuropathy. The designation aims to expedite the review of new therapeutics and may allow for more frequent interactions with the FDA. The company is preparing to dose the first patient in its Phase 1/2 study and expects to share data once available. The STAND study will assess the safety, tolerability, and preliminary efficacy of ST-503 in patients with SFN.